Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
Shanghai Chest Hospital · Shanghai Jiao Tong University · +25 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
195
total citations
- FWCI
- 42.95
- Percentile
- 100%
- References
- 24
Citations per year
Authors
26Topics & keywords
Topics
Keywords
- Pemetrexed
- Medicine
- Internal medicine
- Chemotherapy
- Lung cancer
- Oncology
- Interim analysis
- Response Evaluation Criteria in Solid Tumors
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.